Table 10.

Liver Function Indexes Before and After DEB-TACE Treatment in Patients With Abnormal Liver Function-Related Indexes at Baseline

	Baseline	1 Week After DEB-TACE	1–3 Months After DEB-TACE	p Value*	p Value†
ALB (g/L) (n = 177)	34.3 (32.1–37.0)	31.4 (28.2–34.1)	35.1 (31.5–38.0)	<0.001	0.128
TP (g/L) (n = 114)	61.2 (58.6–63.9)	58.6 (52.5–63.6)	66.3 (60.4–72.6)	<0.001	<0.001
TBIL (μmol/L) (n = 104)	29.0 (24.5–40.0)	37.0 (26.9–55.2)	27.0 (17.0–42.0)	<0.001	0.073
TBA (I/L) (n = 145)	29.0 (15.8–49.4)	18.9 (9.3–33.4)	21.9 (12.0–43.0)	<0.001	0.017
ALT (U/L) (n = 93)	59.5 (48.0–84.8)	82.0 (49.0–175.8)	34.0 (23.3–58.3)	<0.001	<0.001
AST (U/L) (n = 166)	59.0 (48.0–88.0)	84.5 (44.3–188.3)	54.5 (36.6–84.5)	<0.001	0.005
ALP (U/L) (n = 169)	195 (157–272)	212 (145–298)	228 (149–334)	0.818	0.055

Data are presented as median (25th–75th). Comparison between each visit was determined by signed Wilcoxon rank sum test. A value of p < 0.05 was considered significant (bold). Analysis was based on DEB-TACE records.

^* p Value of liver function-related biochemical indexes of patients from baseline to 1 week posttreatment.

^† p Value of liver function-related biochemical indexes of patients from baseline to 1–3 months posttreatment.